Pluristem Therapeutics (PSTI) Completes Enrollment for Phase I/II Muscle Injury Trial
7/11/2013 9:20:11 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HAIFA, Israel, July 11, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today it has completed the target enrollment in a randomized, double-blinded, placebo controlled Phase I/II clinical trial to assess the safety and efficacy of its PLacental Expanded (PLX) cells for the treatment of traumatized muscles. All patients have been treated with PLX-PAD cells or placebo and are currently in the follow up stage of the trial.
Help employers find you! Check out all the jobs and post your resume.
comments powered by